Skip to main content

Advertisement

Table 1 Relationship of clinical parameters with LGR5 expression in 126 breast carcinoma patients

From: LGR5 overexpression confers poor relapse-free survival in breast cancer patients

   LGR5 IHC p-value   β-catenin IHC p-value
Variables N Low (%) High (%)   N Low (%) High (%)  
Total 126 68 (54) 58 (46)   119 63 (53) 56 (47)  
Differentiation grade
 I 3 3 (100) 0 (0) 0.072 2 2 (100) 0 (0) 0.377
 II 93 53 (57) 40 (43)   88 45 (51) 43 (49)  
 III 30 12 (41) 18 (59)   29 16 (55) 13 (45)  
Age group
  < = 35 7 5 (71) 2 (29) 0.775 7 4 (57) 3 (43) 0.419
 36–45 28 15 (54) 13 (46)   28 15 (54) 13 (46)  
 46–55 47 27 (57) 20 (43)   42 23 (55) 19 (45)  
 56–65 27 13 (48) 14 (52)   26 10 (38) 16 (62)  
  > 65 17 8 (47) 9 (53)   16 11 (69) 5 (31)  
Tumor size (cm)
  < 2 44 33 (75) 11 (25) 0.002 41 21 (51) 20 (49) 0.910
 2–5 70 40 (43) 30 (57)   66 35 (53) 31 (47)  
  > 5 12 5 (39) 7 (61)   12 7 (58) 5 (42)  
LN metastasis
 Negative 75 46 (61) 29 (39) 0.044 70 36 (51) 34 (49) 0.693
 Positive 51 22 (43) 29 (57)   49 27 (55) 22 (45)  
Histopathological feature
 Invasive ductal carcinoma 121 65 (54) 56 (46) 0.830 114 60 (53) 54 (47) 0.178
 Invasive mucinous carcinoma 1 1 (100) 0 (0)   1 1 (100) 0 (0)  
 Invasive lobular carcinoma 2 1 (50) 1 (50)   2 2 (100) 0 (0)  
 Metaplastic carcinoma 2 1 (50) 1 (50)   2 0 (0) 2 (100)  
ER status
 Negative 49 22 (45) 27 (55) 0.103 46 22 (48) 24 (52) 0.375
 Positive 77 46 (60) 31 (40)   73 41 (56) 32 (44)  
PR status
 Negative 63 31 (49) 32 (51) 0.284 59 30 (51) 29 (49) 0.650
 Positive 63 37 (59) 26 (41)   60 33 (55) 27 (45)  
HER2 status
 Negative 59 27 (46) 32 (54) 0.097 55 35 (64) 20 (36) 0.037
 Positive 66 40 (60) 26 (40)   63 28 (44) 35 (56)  
 Missing 1     1    
Molecular subtype
 Non-TNBC 109 63 (57) 46 (43) 0.029 102 57 (56) 45 (44) 0.115
 TNBC 17 5 (37) 12 (63)   17 6 (35) 11 (65)